Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)

Trespalacios-Rangel, Alba Alicia; Otero, William; Arévalo-Galvis, Azucena; Poutou-Piñales, Raúl A.; Rimbara, Emiko; Graham, David Y.

doi:10.1371/journal.pone.0160007

Cited by 37 publications

(35 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previous studies, H. pylori antibiotic resistance has significantly changed over time [8, 33, 36–38]. For example, in Korea, the resistance rate to clarithromycin increased from 11 to 60% from 2009 to 2014 [39, 40].…”

Section: Discussionmentioning

confidence: 99%

“…In Germany [3] and Brazil [4], the antibiotic resistance rate to clarithromycin was 28.7 and 23.2%, respectively, and it was only 7.3% in Ireland [5] and 0% in Malaysia [6]. The resistance rate to levofloxacin was 32.7% in Buenos Aires [7] and 18.2% in the Bogota-Colombia [8], as well as 5.8% in the Hebei Province of China [9]. As reported in the literature, the resistance rate to amoxicillin and tetracycline is generally low [7, 10, 11], but in Ireland and Vietnam, it was as high as 38.1% [5] and 23.8% [12], respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer

et al. 2019

View full text Add to dashboard Cite

Background H. pylori exhibits antibiotic resistance with regional differences. In this paper, we explored antibiotic resistance of H. pylori to five antibiotics in an area with a high risk of gastric cancer. Results H. pylori resistance rates to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were 78.0, 56.0, 31.0, 9.0, and 15.0%, respectively. Double, triple, quadruple, and quintuple resistance rates were 23, 20, 6, and 4%, respectively. The clarithromycin and multidrug resistance rates were significantly higher in males than females (clarithromycin: 44.4% vs 15.2%, respectively, P = 0.002; multidrug: 75.5% vs 37.2%, respectively; P < 0.001). During the three periods of 1998–1999, 2002–2004 and 2016–2017, the resistance rates to levofloxacin and amoxicillin were increasing (OR: 2.089, 95%CI: 1.142–3.821, P = 0.017; and OR: 5.035, 95%CI: 1.327–19.105, P = 0.018, respectively). The antibiotic resistance rates were unassociated with the host disease state. Metronidazole resistance was lower in the vacA s1m1/m2 group than the vacA s1m1m2 group (65% vs 85.7%, respectively; P = 0.026). As for levofloxacin resistance, it was higher with cagA + than cagA − (60.9% vs 23.1%, respectively; P = 0.020) but lower with slyD + than slyD − (41.4% vs 68.5%, respectively; P = 0.009). Clarithromycin had a lower resistance rate with iceA ++ than iceA −+ (19.7% vs 52.4%, respectively; P = 0.017). For amoxicillin, the iceA ++ group had a lower resistance rate than the iceA −− group (1.6% vs 27.8%, respectively; P = 0.009). Conclusions The total resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, amoxicillin, and tetracycline were high in Zhuanghe. The resistanc rates to levofloxacin and amoxicillin increased over time. Clarithromycin resistance was associated with male and iceA. The resistance of metronidazole was related to vacA. Levofloxacin resistance was concerned with cagA and slyD and amoxicillin resistance was concerned with iceA. While, the antibiotic resistance of H. pylori had nothing to do with the status of gastric disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A study from Colombia also reported increasing resistance, from 11.8% in 2009 to 27.3% in 2014, which was mediated by the gyrA point mutation, and N87I mutation was the most common related to LEVO resistance. 46 Perna et al 47 reported that eradication rates decreased significantly from 75% in LEVO-sensitive patients to 33.3% in patients who had LEVO-resistant H. pylori strains. It seems that in our patient population there is a high prevalence of quinolones resistant H. pylori strains, which led to poor treatment outcomes in the LEVO-based therapy group as compared to the CLA-based therapy group.…”

Section: Discussionmentioning

confidence: 99%

<p>Reevaluation of the Efficacy of First Line Regimen for <em>Helicobacter pylori</em></p>

Tariq¹,

Patel²,

Kamal³

et al. 2020

CEG

View full text Add to dashboard Cite

Background: Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge. Aim: There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population. Methods: This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy. Results: A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001). Conclusion: In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully.

show abstract

“…Generally, the high dose of antibiotics contributes to some side effects, such as gastrointestinal reaction, skin allergic reaction and nervous system response [36]. A more serious problem is that long-term use of levo oxacin leads to drug resistance [37]. Therefore, a new strategy to reduce the use of high doses of antibiotics is needed.…”

Section: Gp-682 Micelles Changed the Distribution Of Levo Oxacin In Mmentioning

confidence: 99%

Micelles self-assembled by 3-O-β-D-glucopyranosyl latycodigenin enhances cell membrane permeability, promotes antibiotic pulmonary targeting and improves anti-infect efficacy

Zhang

Huang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Nanoparticle-based pulmonary drug delivery systems are commonly developed and applied for drug-targeted delivery. It exhibits significant advantages compared to traditional pulmonary drug delivery systems. However, developing a formulation for each drug is a time-consuming and laborious task. Results: The present study designed and constructed a universal lung-targeting nanoparticle. The self-assembled micelles were composed of a platycodon secondary saponin, 3-O-β-D-glucopyranosyl platycodigenin 682 (GP-682), via its specific amphiphilic structure. After optimization, the GP-682 micelles obtained a stable zeta potential with a particle size between 60 to 90 nm, and the CMC value was approximately 42.3 μg/mL. Pre-incubation of GP-682 micelles markedly enhanced the cell membrane permeability, and improved drug uptake in vitro . The results were visualized using fluorescent dye tracing, transmission electron microscopy observation and a lactate dehydrogenase releasing assay. The benefits enhanced the distribution of levofloxacin in mouse lung tissue and reduced the overdosing of antibiotic. Pseudomonas aeruginosa PA 14 strain-induced acute lung injury mice model demonstrated that preinjection of GP-682 micelles followed by antibiotic administration produced a higher survival rate and anti-infection efficacy in vivo , which included a reduction in pulmonary injury, bacterial invasion and the expression of cytokines compared to treatment with levofloxacin alone. Conclusions: GP-682 micelles are another nanoparticle-based pulmonary drug delivery system to increase the use of antibiotic and provide a new option for antibiotic resistance and lung-targeting therapy.

show abstract

Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014)

Cited by 37 publications

References 46 publications

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer

The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer

<p>Reevaluation of the Efficacy of First Line Regimen for <em>Helicobacter pylori</em></p>

Micelles self-assembled by 3-O-β-D-glucopyranosyl latycodigenin enhances cell membrane permeability, promotes antibiotic pulmonary targeting and improves anti-infect efficacy

Contact Info

Product

Resources

About